Helsinn Healthcare SA
6912 Pazzallo-Lugano
Via Pian Scairolo
9
Tel: 41-91-985-21-21
Fax: +41-91-993-21-22
Website: http://www.helsinn.com/
Email: info@helsinn.com
About Helsinn Healthcare SA
Helsinn is a privately owned cancer care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.YEAR FOUNDED:
1976
JOBS:
Please click here for Helsinn job opportunities.
PRODUCTS:
All Products
FOLLOW HELSINN:
Tweets by Helsinn
39 articles about Helsinn Healthcare SA
-
Zealand Pharma And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea
2/5/2015
-
Helsinn Healthcare SA And Zealand Pharma Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea
2/5/2015
-
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI®
1/12/2015
-
Zealand Pharma and Helsinn Healthcare SA Announce Helsinn’s Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea
5/28/2013
-
Zealand Pharma Receives Milestone Payment from Helsinn Healthcare SA
12/9/2010
-
Helsinn Healthcare SA and Eisai Inc. Extend Relationship
6/9/2010
-
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc.
1/28/2009
-
Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma
12/11/2008
-
Zealand Pharma and Helsinn Healthcare SA Sign a €140 Million (US$176.8 Million) Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
12/2/2008
-
MGI PHARMA, INC. and Helsinn Healthcare SA Announce sNDA for Aloxi Capsules Accepted for Review by U.S FDA
1/3/2008
-
MGI PHARMA, INC. and Helsinn Healthcare SA Announce Submission of Supplemental New Drug Application for Aloxi(R) Capsules
10/30/2007
-
MGI PHARMA, INC. and Helsinn Healthcare SA Announce Aloxi(R) sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens
9/4/2007
-
MGI PHARMA, INC. and Helsinn Healthcare SA Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA
7/9/2007
-
MGI PHARMA, INC. and Helsinn Healthcare SA Announce Submission of Supplemental New Drug Application for Aloxi(R) Injection in Post-Operative Nausea and Vomiting
5/7/2007
-
MGI PHARMA, INC. And Helsinn Healthcare SA Announce Patent Extension For Aloxi(R) Injection
2/13/2007
-
MGI PHARMA, INC. And Helsinn Healthcare SA Announce Positive Phase 3 Results For Aloxi(R) (Palonosetron Hydrochloride) Injection For The Prevention Of Post Operative Nausea & Vomiting
12/14/2006
-
The Day In Review: Another Indication For Herceptin From Genentech, Inc.
11/17/2006
-
EKR Therapeutics Acquires Exclusive License For Gelclair® From Helsinn Healthcare SA
10/12/2006
-
Helsinn Healthcare SA And Biovitrum AB Enter A License Agreement For Nordic Marketing Of Aloxi(R)
2/16/2006